- Kristi Powers
Choose the health content that’s right for you, and get it delivered right in your inbox.
AdventHealth is the first in the U.S. and the only health system in Florida to offer this new ‘precision medicine’ treatment.

A new way of treating bladder cancer is now available to patients in Central Florida via a Phase II randomized trial at the AdventHealth Cancer Institute. This is the only site in Florida, and the first in the U.S., to open this groundbreaking treatment, known as the INTerpath-005 V940 mRNA vaccine Phase II trial.
“This vaccine is precision medicine at its best,” Dr. Guru Sonpavde, a medical oncologist at the AdventHealth Cancer Institute, as well as a member of the trial’s global steering committee, recently told Central Florida Health News. “Unlike most trials where all patients receive one specific drug, some of the patients in this trial will receive a new drug customized to target the specific mutated proteins only found in the cancer cells of that patient.”

Participants will receive pembrolizumab (KEYTRUDA) combined with the new customized immunotherapy injection. KEYTRUDA alone has previously improved outcomes following surgical removal of aggressive muscle-invasive urothelial cancer.
“This V940 drug is exciting in that it codes for 34 neoantigens (which are new mutated proteins) found only in cancer cells and this is injected into the patient intramuscularly every three weeks for up to nine times,” Sonpavde discussed with Becker’s on their Healthcare podcast. “This (drug) is extremely specific immunotherapy which looks highly promising.”
Sonpavde believes this trial offers a tailored treatment against bladder cancer.
”I’m optimistic the combination drug treatment, the V940 vaccine plus KEYTRUDA, in this trial will be safe and successful and will lead to a Phase III trial,” he recently told the American Hospital Association.
He envisions this custom treatment to become more widely available worldwide soon. Bladder cancer patients don’t have to wait years for access, the trial is now open. Patients need a referral and should ask their doctor if they’re interested.
For more information, contact the AdventHealth Clinical Research GU Coordinator at ORL.GU.ClinicalTrials@AdventHealth.com.
Recent News
Lake Mary Little League®, home of the 2024 Little League® World Series Champions, is proud to announce a new partnership with AdventHealth.
Every year, the American Heart Association recognizes programs that perform exceptionally in the area of stroke. We are proud to announce AdventHealth Avista, AdventHealth Littleton, AdventHealth...
Following AdventHealth’s mission to help team members, guests and patients Feel Whole, AdventHealth Castle Rock officially opened the Pittman Pathway Wellness Trail with a ribbon cutting ceremony.
Dr. Matthew Villani, a foot and ankle surgeon with AdventHealth Medical Group located at AdventHealth Waterman, addresses foot and ankle injuries.
AdventHealth Millenia ER is celebrating its first anniversary of providing lifesaving, whole-person care to residents and visitors in West Orlando.
Anesthesia Associates of Kansas City becomes a strategic partner for the rapidly growing hospital in south Overland Park.
UChicago Medicine AdventHealth Hinsdale now offers life-saving stroke care with a new minimally invasive procedure, improving survival rates and quality of life.
The hospital’s three-story expansion will be completed in summer 2026.
AdventHealth Zephyrhills is leading the way in Pasco County with a new treatment for clostridioides difficile or C. diff.
AdventHealth is proud to introduce you to Frannette Miller, BSN, RN, winner of our DAISY Award for the ray of light she shines on the lives of her patients every day in the Behavioral Health Unit at...
AdventHealth President/CEO David Banks reveals three benefits of practicing design thinking.
Dr. Jason Jennings, orthopedic surgeon with AdventHealth Medical Group Colorado Joint Replacement at Porter, was selected to present his research findings at the 3rd International Consensus Meeting on...